Decision Diagnostics Corp. and Its Subsidiary PharmaTech Solutions, Inc. Sue Johnson & Johnson Division LifeScan, Inc. and

Decision Diagnostics Corp. and Its Subsidiary PharmaTech Solutions, Inc. Sue 
Johnson & Johnson Division LifeScan, Inc. and LifeScan
Scotland Ltd. for Antitrust Violations 
Company Seeks to End Pharmaceutical Giant's Tactics in Restraint of
Trade Action 
LOS ANGELES, CA -- (Marketwired) -- 04/04/13 --  Decision Diagnostics
Corp. (OTCBB: DECN) the exclusive world-wide sales, service and
regulatory processes agent for the Shasta GenStrip, the revolutionary
at-home glucose test strip specifically designed to work with the
Johnson & Johnson's LifeScan family of glucose testing meters,
announced today that on March 28, 2013 the company and its subsidiary
PharmaTech Solutions, Inc. filed antitrust counterclaims against
LifeScan, Inc. and LifeScan Scotland, Ltd. (collectively, "LifeScan")
in a patent action brought by LifeScan (2011cv04494) that is
presently pending in the Northern District of California. DECN and
PharmaTech are defendants in that action. DECN is a leading provider
of prescription and non-prescription diagnostics, home testing
products for the chronically ill and a premier developer of
revolutionary cell phone centric e-health products and technologies. 
The counterclaims assert violations of the Sherman Antitrust Act,
which carry with them, if successful, awards of treble damages,
attorneys' fees, and injunctive relief. DECN and PharmaTech allege
that the LifeScan parties, which are subsidiaries of pharmaceutical
giant Johnson & Johnson, have violated both Sections 1 and 2 of the
Sherman Act. Section 1 makes illegal every "contract, combination. .
. or conspiracy in restraint of trade." Section 2 forbids
monopolization and attempts to monopolize a product market. DECN and
PharmaTech allege in their counterclaims that both prongs of the Act
have been violated, by among other things, LifeScan's instituting of
baseless patent litigation against PharmaTech and DECN intended to
exclude the Shasta GenStrip from competing in a market dominated by
LifeScan and Johnson & Johnson have long claimed to be the market
leader in the home blood glucose monitoring market, boasting an over
thirty percent (30%) share of that market. The market is highly
concentrated, dominated by four major pharmaceutical companies which
together control 83.5% of that market. Blood glucose monitoring
systems are comprised of a monitor and testing strips. Significantly,
until the potential entry of the Shasta GenStrip, all four market
leaders paired their propriety blood glucose meters with their own
testing strips, forestalling any competition from competing strips,
which could offer substantial costs savings to consumers. The FDA 's
recent clearance of the GenStrip for use with certain OneTouch Ultra
meters clears the way for such competition and for the substantial
consumer savings it would bring. 
The antitrust counterclaims allege that, to maintain its much-vaunted
market leadership in the blood glucose monitoring market, LifeScan
has illegally "tied" the use of its popular OneTouch Ultra meters to
its own proprietary testing strips. Tying arrangements violate
Section 1 of the Sherman Act because they force purchasers to forego
free choice in the marketplace. These "tying" transactions are often
declared to be illegal "per se," that is, so plainly in contravention
of antitrust principles that they require no further analysis of
effects on competition. 
The counterclaim alleges that, to the extent that LifeScan claims its
meters (glucose measuring device) are protected by patent, which DECN
and PharmaTech vehemently dispute, LifeScan has no right to expand
any such rights to control the sale of strips. There is no functional
reason to require consumers to use the LifeScan strips, nor is there
any patent justification. PharmaTech and DECN claim that LifeScan has
taken numerous steps, including the institution of baseless patent
litigation, to eliminate competition and to exclude the GenStrip from
the market so as to require exclusive use of the LifeScan strips with
the OneTouch Ultra meter. These tactics violate longstanding and
fundamental antitrust principles. They injure consumers by forbidding
competition from the lower-priced GenStrip. Second, DECN and
PharmaTech also allege that LifeScan has monopolized and is
attempting to monopolize the market for test strips compatible with
LifeScan's meters and has created a dangerous probability of success.
These acts have no basis in any patent or functional principal, and
only serve the purpose of preserving LifeScan's market dominance. 
GenStrip(TM) test strips are a product of Shasta Technologies, LLC
and are not manufactured, distributed, endorsed, or approved by nor
associated with LifeScan(R), Inc., a Johnson & Johnson(R) Company,
manufacturers and distributors of the OneTouch(R) Ultra(R) Family of
Meters and OneTouch(R) Ultra(R) test strips. 
Forward-Looking Statements: 
Forward-looking statements are statements made herein which do not
address historical facts and, therefore, could be interpreted to be
forward-looking statements. We can give no assurance that the
expectations indicated by such forward-looking statements will be
realized. There may be other risks and circumstances that we are
unable to predict. When used in this release, words such as
"believes," "expects," "forecasts," "intends," "projects," "plans,"
"anticipates," "estimates" and similar expressions are intended to
identify forward-looking statements, although there may be certain
statements not accompanied by such expressions. Such statements are
subject to factors that could cause actual results to differ
materially from anticipated results. The forward-looking statements
included in this press release represent our views as of March 31,
2013. We anticipate that subsequent events and developments may cause
our views to change. 
Keith Berman
Secretary and CFO
2660 Townsgate Road 
Suite 300
Westlake Village, CA 91361
Ph: 805-446-2973
Fax: 805-446-1983 
Press spacebar to pause and continue. Press esc to stop.